The ERK signaling pathway is one of the most commonly deregulated pathways in cancer. Assays that accurately measure ERK signaling output in clinical specimens would be extremely helpful not only in determining the pharmacodynamic effects of drug treatment but also in selecting those patients most likely to respond to therapy. Clin Cancer Res; 23(6); 1365–7. ©2016 AACR.
See related article by Brant et al., p. 1471
- Received November 4, 2016.
- Accepted November 9, 2016.
- ©2016 American Association for Cancer Research.